Innate Pharma (XPAR:IPH) Short-Term Debt : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Short-Term Debt?

Innate Pharma's Short-Term Debt for the quarter that ended in Dec. 2024 was €0.00 Mil.

Innate Pharma's quarterly Short-Term Debt declined from Dec. 2023 (€8.45 Mil) to Jun. 2024 (€0.00 Mil) but then stayed the same from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Innate Pharma's annual Short-Term Debt increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€8.45 Mil) but then declined from Dec. 2023 (€8.45 Mil) to Dec. 2024 (€0.00 Mil).

Innate Pharma Short-Term Debt Historical Data

The historical data trend for Innate Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Short-Term Debt Chart

Innate Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

1.37

29.94

8.45

Innate Pharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															-	-	8.45	-	-

Innate Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Innate Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDD:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines